Rigaku Raman Technologies Handheld Raman Analyser Progeny Wins IBO Award for Portable Analytical Instrument Industrial Design
Rigaku Raman Technologies, a leading pioneer of handheld and portable Raman spectrometers, is delighted to announce that its handheld Raman analyser, Progeny has received the Bronze Award for the Portable Analytical Instrument Industrial Design category in the 2014 Instrument Business Outlook (IBO) Design Awards. Progeny represents the new generation in handheld Raman analysis for comprehensive material identification and analysis across applications including raw material identification in the pharmaceutical industry and chemical detection for first responders.
The annual IBO Awards recognise excellence in the industrial design of analytical instruments, portable analytical instruments and laboratory equipment. Judged on innovation, functionality and product features, the winners were selected based on designs that improve product functionality and the end-user experience. In the Portable Analytical Instrument Industrial Design category, winning products were not only chosen for being compact and stylish but also how they address the unique challenges of doing analysis outside of the laboratory.
Progeny is designed to provide superior performance, design and usability for the identification of unknown materials. Weighing just 3.5 lbs, Progeny’s lightweight aluminum housing is sealed against moisture, dust and other potential contaminants to prevent contamination and enables use in any environment with an IP-68 protection rating. The ergonomics of the instrument were carefully considered to provide a comfortable user experience and Progeny’s user-friendly angled display, touchscreen interface provides easy, single-hand use. Compared to other handheld Raman analysers, Progeny provides enhanced performance capabilities for the measurement of colored materials or through dark containers by eliminating fluorescence interference with the use of a unique 1064-nm laser.
Bree Allen, VP and General Manager at Rigaku Raman Technologies, commented on the award win: “We are delighted that Progeny has been recognised with this prestigious award. With Progeny, we exceeded all of our initial expectations by redefining the performance, ruggedness and ease of use that can be experienced when using handheld Raman for material identification. Rigaku Raman is committed to setting new benchmarks in Raman spectroscopy. With Progeny, we have developed a product that we believe will revolutionise what can be achieved with handheld Raman across a multitude of applications.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.